Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of a standard dose of telmisartan combined with amlodipine and trichlormethiazide versus a high dose of telmisartan combined with trichlormethiazide on urinary excretion of albumin in hypertensive patients with type 2 diabetes mellitus.

Next Previous
Trial Profile

Effect of a standard dose of telmisartan combined with amlodipine and trichlormethiazide versus a high dose of telmisartan combined with trichlormethiazide on urinary excretion of albumin in hypertensive patients with type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Telmisartan (Primary) ; Trichlormethiazide
  • Indications Diabetic nephropathies; Essential hypertension; Proteinuria
  • Focus Therapeutic Use
  • Acronyms ESTIMATE-A

Most Recent Events

  • 04 Oct 2012 Primary endpoint 'Albumin-excretion-rate' has been met.
  • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
  • 03 Mar 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top